This section assesses the plan from the perspectives that matter most to lenders and equity investors: debt-service cover, capital efficiency, and risk-adjusted returns, with the clinic rollout ramp as the central sensitivity and a clear-eyed treatment of why the returns are so high and where the risks lie.
Debt-service cover — the early-year gap
|
Metric |
Year 1 |
Year 2 |
Year 3 |
Year 4 |
Year 5 |
|---|---|---|---|---|---|
|
CFADS |
-8 |
36 |
126 |
145 |
172 |
|
Debt service |
5 |
13 |
18 |
57 |
62 |
|
DSCR (x) |
-1.54x |
2.73x |
7.08x |
2.53x |
2.77x |
|
Net debt / EBITDA (x) |
n/m |
0.76x |
0.72x |
-0.06x |
-0.61x |
|
ROCE |
-5.9% |
-0.4% |
11.5% |
21.7% |
24.2% |
Analyst flagDebt is not serviceable from operations in Year 1 — structure for it
Because EBITDA is negative in Year 1 while the first clinics ramp, the debt-service cover ratio is negative that year, and the network only comfortably covers debt service from Year 2. The financing must therefore be structured with a principal grace period through the early rollout (modelled) and a debt-service reserve funded from the raise to meet interest until the network turns cash-generative. This is normal for a capital-intensive healthcare rollout, but it is non-negotiable: cover ratios must be read across the rollout, not on a steady-state basis.
Returns — exceptional, and why
On the sponsor’s targets, revenue exceeding R1.2 billion and a ~22% EBITDA margin, exited at a conservative 8.5x EV/EBITDA on Year-5 EBITDA of about R267 million, the plan delivers a project IRR near 86%, an equity IRR of about 72%, and a money multiple around 8.7x. These returns are exceptional, and they are so for a specific structural reason: the business is capital-light relative to its earnings. A R450 million programme supports a business generating some R267 million of EBITDA by Year 5, more than half its entire funding base, so a modest equity cheque is levered against a business worth over R2 billion at exit. The returns are real arithmetic, but they are a ceiling contingent on delivering the rollout and, above all, the staffing.
|
Rollout ramp vs plan |
80% |
90% |
100% |
110% |
120% |
|---|---|---|---|---|---|
|
Equity IRR |
63% |
68% |
72% |
76% |
79% |
Analyst flagRead the returns as a ceiling — and underwrite the staffing plan
Three honest caveats attach to the headline returns. First, they assume the nine clinics are built, staffed and ramped on plan; a combined-stress scenario, a 20% weaker ramp, a 20% lower margin and an 8x exit, still returns roughly 53%, cushioned by the light capital base, but that resilience is a feature of the small equity cheque, not evidence the base case is safe. Second, and above all, the returns are gated by ophthalmologist supply: if the clinics cannot be staffed, particularly the rural ones, the revenue, and therefore every return figure, simply does not materialise. Third, the surgical-throughput target (20,000 procedures, ~1,100 per specialist) is ambitious and must be validated. Investors should underwrite the recruitment and throughput plan, not the headline IRR.
Three-case scenario analysis
Framing the decision as three underwriteable cases is more honest than a single headline. The combined-stress case, a 20% weaker ramp, a 20% lower margin and an 8x exit, returns roughly 53%; the base case (the sponsor targets at 8.5x) returns about 72%; the upside case (a stronger ramp at a premium multiple) is higher still. Every case clears the 18% cost of equity comfortably, the point being that, on a capital base this light, the question is not whether the equity is in the money but whether the aggressive base case can be delivered, which turns on staffing above all.
|
Combined stress |
Base |
Upside |
|
|---|---|---|---|
|
Scenario |
Ramp –20%, margin –20%, 8x |
Sponsor targets, 8.5x |
Ramp +20%, 12.5x |
|
Equity IRR |
53% |
72% |
96% |
|
Assessment |
Still well above hurdle |
Ceiling case |
Exceptional |
Two-dimensional sensitivity — rollout ramp and exit multiple
The two variables that most drive the equity return are the rollout ramp (which sets the mature EBITDA) and the exit multiple (which capitalises it). The grid below shows equity IRR across both simultaneously. A weak ramp exited at a low multiple is the genuine downside corner; a strong ramp exited at a premium healthcare multiple is the upside.
|
Ramp \\ Exit x |
8.0x |
9.5x |
11.0x |
12.5x |
|---|---|---|---|---|
|
80% ramp |
61% |
67% |
73% |
78% |
|
90% ramp |
65% |
72% |
78% |
83% |
|
100% ramp |
69% |
76% |
82% |
88% |
|
110% ramp |
73% |
80% |
87% |
92% |
|
120% ramp |
77% |
84% |
91% |
96% |
Even in the bottom-left corner, a weak ramp exited at 8x, the return remains well above the cost of equity, because the capital base is so light. This resilience is genuine, but it should not lull investors: the grid assumes the clinics are staffed and running. The variable that is not on this grid, whether eighteen ophthalmologists can be recruited and retained across nine provinces, is the one that most determines whether any of these outcomes is achieved.
Indicative covenant package
The plan is structured to sit within a healthcare project-finance covenant package designed for the rollout, with the early-year cover gap managed through a grace period and a funded reserve.
|
Covenant / structural feature |
Indicative level |
Rationale |
|---|---|---|
|
Principal grace period |
Through the early rollout |
Debt not serviceable from operations in Year 1 |
|
Debt-service reserve |
6–12 months’ service, funded at close |
Meets interest until the network is cash-generative |
|
Working-capital facility |
Committed, sized to receivables |
Funds medical-aid receivable book through the ramp |
|
Minimum DSCR (steady state) |
≥ 1.30x from Year 2 |
Applies once clinics are contributing |
|
Clinic-opening / staffing covenant |
Monitored vs plan |
Early-warning trigger on the binding constraints |
|
Dividend lock-up |
Until cover & leverage tests met |
Retains cash through the rollout |
Valuation and exit
The base case applies a conservative 8.5x EV/EBITDA exit multiple to Year-5 EBITDA of about R267 million, implying an enterprise value around R2.27 billion and equity value of roughly R2.43 billion after net cash. An 8.5x multiple is restrained for a growing, integrated specialist-healthcare platform, South African private-hospital and day-surgery groups have traded higher, and the sensitivity grid shows how returns move at 8 to 12.5x. Four credible exit routes support liquidity: a trade sale to a private-hospital or healthcare group seeking an integrated eye-care platform, a private-equity secondary, a listing, or a long-term hold generating strong dividends. The scarcity value of a built, staffed, national eye-care network, precisely because it is so hard to assemble, is what a strategic acquirer would pay for.
|
Exit metric |
Value |
|---|---|
|
Year-5 EBITDA |
~R267m |
|
Exit multiple (EV/EBITDA) |
8.5x |
|
Implied enterprise value |
~R2,270m |
|
Implied equity value (net of cash) |
~R2,432m |
|
Project IRR / equity IRR |
~86% / ~72% |
|
Money multiple (MOIC) |
~8.7x (a ceiling) |
Financing process and next steps
- Mandate & structuring of the R170m debt facility with a grace period, a funded debt-service reserve and a committed working-capital facility for medical-aid receivables.
- Specialist-recruitment due diligence — a credible, province-by-province plan to recruit and retain the ophthalmologists, the single most important condition precedent.
- Medical-aid & referral contracting network agreements with major schemes and GP/optometrist referral relationships to validate the ramp.
- Equity close of R280m ahead of first drawdown, with staged, milestone-linked debt disbursement tied to clinic build and opening.